Peptide Index

Non-peptide small molecule often grouped with peptide-adjacent longevity / body-composition compounds

Recombinant ActRIIB-Fc ligand trap / myostatin-pathway biologic

Topical cosmetic peptide used primarily for wrinkle appearance claims

Experimental adipose-vasculature targeting peptidomimetic

AMP analog / AMPK-pathway research compound also known as acadesine or AICAr in strict nomenclature

Prostaglandin E1 analog drug with established regulated medical use

Growth-hormone fragment analog developed for fat-loss research and later commercial repositioning

Tissue-protective erythropoietin-derived peptide also developed as cibinetide

Bacteriostatic Water for Injection, a diluent rather than a peptide

Neurotoxin biologic class used therapeutically and cosmetically

Experimental gastric pentadecapeptide widely promoted for healing and recovery, with limited human evidence

Short respiratory-system bioregulator peptide from the Russian peptide-bioregulator literature

Long-acting amylin analogue in advanced obesity development

Short cardiac-focused bioregulator peptide with limited preclinical evidence

Cartilage-focused ultrashort peptide bioregulator

Porcine brain-derived peptide mixture used in some countries for neurological indications

Long-acting GHRH analogue with Drug Affinity Complex extension

Shorter-acting modified GHRH analogue often marketed as Mod GRF (1-29)

Bronchial bioregulator tripeptide linked to inflammatory-modulation claims

Synthetic vitamin B12; approved nutrient-replacement therapy rather than a peptide

Amphibian heptapeptide mu-opioid agonist; research compound, not an approved medicine

Delta sleep-inducing peptide; controversial nonapeptide with mixed sleep and neuroregulatory evidence

Synthetic pineal tetrapeptide also known as Epitalon; longevity and pineal-signaling claims remain non-approved

Endogenous erythropoietin and epoetin-class therapeutic reference entry; glycoprotein hormone, not a simple peptide

FOXO4-DRI senolytic peptide reference entry; repository note added because market shorthand often says simply "FOXO4"

Endogenous activin and myostatin-binding glycoprotein; usually discussed through gene-therapy or pathway-modulation strategies

Growth differentiation factor 8, also known as myostatin; target-biology entry rather than a standard administered peptide

Copper-complexed GHK tripeptide used mainly in topical skin and tissue-repair research

Synthetic ghrelin-receptor agonist hexapeptide; pralmorelin reference entry with region-specific diagnostic use

Classic synthetic ghrelin-receptor agonist hexapeptide; research and gray-market peptide without mainstream therapeutic approval

Endogenous incretin peptide and class-anchor biology for GLP-1 receptor agonist therapeutics

Endogenous antioxidant tripeptide; broad basic-biology importance with mixed intervention evidence across routes and use cases

Human chorionic gonadotropin; clinically established glycoprotein hormone for fertility and endocrine use, not a simple short peptide

Synthetic ghrelin-receptor agonist hexapeptide; potent growth-hormone secretagogue with research-only status

Recombinant human growth hormone; approved 191-amino-acid biologic with extensive pediatric and adult endocrine use

C-terminal human growth hormone fragment; widely marketed for fat-loss claims but much less validated than somatropin or approved obesity drugs

Human menopausal gonadotropin (menotropins); mixed FSH/LH activity fertility biologic rather than a single discrete peptide

Matrix glycosaminoglycan used across dermatology, aesthetics, ophthalmology, and device-based medicine; not a peptide

Long R3 IGF-1 analog with reduced IGF-binding-protein interaction; potent experimental growth factor with no approved human use

Des(1-3)IGF-I truncated analog / cleavage product with reduced binding-protein interaction and no approved therapeutic status

Endogenous peptide hormone and major approved biologic drug class for diabetes; not a niche research peptide

Selective ghrelin-receptor agonist pentapeptide; experimental growth-hormone secretagogue without mainstream therapeutic approval

Decapeptide fragment of kisspeptin; reproductive-neuroendocrine research peptide with active human investigation but no mainstream approval

Lys-Pro-Val tripeptide from alpha-MSH; anti-inflammatory research peptide with topical and gut-delivery interest but no approved drug status

Human cathelicidin antimicrobial peptide (LL-37); innate-immunity and wound-healing peptide with real clinical investigation but no broad approval

Dual GLP-1 / glucagon receptor agonist peptide approved in China; modern metabolic drug rather than a gray-market peptide

Afamelanotide / Melanotan-1 analog of alpha-MSH; approved medicine under the afamelanotide name but often confused with gray-market tanning products

Synthetic cyclic melanocortin analog associated with tanning and sexual-function claims; not an approved mainstream medicine

Endogenous indoleamine sleep-regulating hormone; not actually a peptide, but included as an adjacent bioactive because it appears in peptide-use lists

Mechano Growth Factor / IGF-1Ec shorthand; biologically important transcript concept but a highly ambiguous commercial peptide entry

Mitochondrial-derived 16-amino-acid peptide linked to metabolic-stress signaling; the parent peptide remains research-stage, with the most concrete human-development work occurring through analog programs such as CB4211 rather than a marketed MOTS-c drug.

Endogenous redox coenzyme and dinucleotide; not actually a peptide, but commonly grouped with peptide and longevity catalogs because of IV / IM wellness-market use and mitochondrial-aging narratives.

Peptide-bioregulator market entry with conflicting public identity data; this record is intentionally provenance-heavy because tissue target, sequence assignment, and even product positioning vary across public sources.

Synthetic oxytocin nonapeptide, usually encountered in approved medicine as oxytocin and in research catalogs with acetate salt labeling; a mainstream established peptide hormone rather than a fringe peptide-market item.

Tetrapeptide bioregulator most often described with the sequence Lys-Glu-Asp-Trp (KEDW); positioned in Russian and peptide-bioregulator literature around pancreatic aging, glucose regulation, and endocrine support.

Short synthetic neuro-focused peptide bioregulator usually described as the tripeptide Glu-Asp-Arg (EDR); associated with cognition, neuroprotection, and aging claims in the Khavinson peptide literature.

Experimental anticancer chimeric peptide derived from the p53 HDM-2-binding region and a membrane-penetrating sequence; notable in preclinical oncology but not an approved human cancer therapy.

PT-141 is the development and market shorthand for bremelanotide, a cyclic melanocortin agonist approved in the United States as Vyleesi for acquired generalized hypoactive sexual desire disorder in premenopausal women.

Investigational once-weekly lipidated peptide designed as a triple agonist at GLP-1, GIP, and glucagon receptors; one of the most important non-approved metabolic peptide programs currently in late-stage development.

Long-acting 31-amino-acid GLP-1 analog approved across multiple major brands and formulations for type 2 diabetes and chronic weight-management–related indications; one of the defining modern peptide medicines.

Synthetic heptapeptide tuftsin analogue used mainly as a Russian anxiolytic / nootropic drug and research peptide rather than a broadly approved international medicine.

Synthetic ACTH(4-10)-derived heptapeptide nootropic / neuroactive drug used mainly in Russia and neighboring markets, with limited mainstream Western regulatory adoption.

Synthetic 29-amino-acid GHRH fragment analog with historical U.S. approval history, later market withdrawal, and ongoing off-label / compounding interest.

Nomenclature-ambiguous exercise-mimetic research compound; public primary literature centers on SLU-PP-332, a non-peptide ERR agonist, rather than a validated peptide called SLU-PP-322.

Cosmetic acetylated octapeptide, also known as acetyl octapeptide-3, positioned mainly as a topical anti-wrinkle ingredient rather than a systemic drug peptide.

Mitochondria-targeted tetrapeptide, also known as elamipretide, now carrying U.S. accelerated approval in Barth syndrome while still under broader investigation in mitochondrial disease.

Investigational once-weekly dual glucagon / GLP-1 receptor agonist in late-stage development for obesity, overweight-related disease, and MASH-associated programs.

Market shorthand for thymosin-beta-4-related repair peptides, with strong preclinical regeneration biology but unsettled product identity and weak standardized human evidence under the TB-500 label.

Synthetic 44-amino-acid GHRH analog approved in the United States for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy.

Ultrashort bioregulator peptide most commonly described as KEDG, marketed for endocrine / healthy-aging support claims but supported mainly by limited bioregulator literature rather than mainstream drug development.

Thymus-derived polypeptide extract immunomodulator with regional clinical history, but not a single defined peptide sequence in the way modern peptide drugs are.

Synthetic 28-amino-acid thymic peptide immunomodulator (thymalfasin) approved in many countries, but not in the United States, with a substantial human literature across infectious and immune-related contexts.

Dual GIP / GLP-1 receptor agonist peptide approved across major brands for type 2 diabetes and chronic weight-management indications, with rapidly expanding clinical and regulatory importance.

Synthetic GnRH agonist decapeptide with established approval history in prostate cancer and central precocious puberty, plus broader reproductive-endocrine use in some markets.

Ultrashort vascular bioregulator peptide, often transliterated as Vezugen, with a narrow literature base focused on endothelial / vascular aging contexts rather than mainstream drug development.

Endogenous 28-amino-acid vasoactive intestinal peptide with broad physiologic importance and intermittent therapeutic development, though native VIP itself is not a mainstream approved drug product.

Synthetic dipeptide bioregulator (Lys-Glu) associated with thymic and geroprotector literature, but supported mainly by small-scale regional and preclinical evidence rather than mainstream therapeutic development.